Rebekka Wegmann
Overview
Explore the profile of Rebekka Wegmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wegmann R, Bonilla X, Casanova R, Chevrier S, Coelho R, Esposito C, et al.
Nat Commun
. 2024 Oct;
15(1):9402.
PMID: 39477946
Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug...
2.
Wegmann R, Bankel L, Festl Y, Lau K, Lee S, Arnold F, et al.
Nat Commun
. 2024 Oct;
15(1):8544.
PMID: 39358333
Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells from patient biopsies. Here, we comprehensively characterize a pan-cancer cohort of 150 malignant...
3.
Lee S, Weiss T, Buhler M, Mena J, Lottenbach Z, Wegmann R, et al.
Nat Med
. 2024 Sep;
30(11):3196-3208.
PMID: 39304781
Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities...
4.
Christodoulou D, Mukherjee A, Wegmann R, Pagano A, Sharma V, Linker S, et al.
bioRxiv
. 2023 Sep;
PMID: 37662202
According to a widely accepted paradigm of microbiology, steady-state growth rates are determined solely by current growth conditions and adaptations between growth states are rapid, as recently recapitulated by simple...
5.
Kropivsek K, Kachel P, Goetze S, Wegmann R, Festl Y, Severin Y, et al.
Nat Cancer
. 2023 Apr;
4(5):734-753.
PMID: 37081258
Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of...
6.
Eichhoff O, Stoffel C, Kasler J, Briker L, Turko P, Karsai G, et al.
Cancer Res
. 2023 Mar;
83(7):1128-1146.
PMID: 36946761
Significance: Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.
7.
Cherkaoui S, Durot S, Bradley J, Critchlow S, Dubuis S, Masiero M, et al.
Mol Syst Biol
. 2022 Nov;
18(11):e11033.
PMID: 36321552
Cancer cells reprogram their metabolism to support growth and invasion. While previous work has highlighted how single altered reactions and pathways can drive tumorigenesis, it remains unclear how individual changes...
8.
Irmisch A, Bonilla X, Chevrier S, Lehmann K, Singer F, Toussaint N, et al.
Cancer Cell
. 2021 Jan;
39(3):288-293.
PMID: 33482122
The application and integration of molecular profiling technologies create novel opportunities for personalized medicine. Here, we introduce the Tumor Profiler Study, an observational trial combining a prospective diagnostic approach to...
9.
Wegmann R, Neri M, Schuierer S, Bilican B, Hartkopf H, Nigsch F, et al.
Genome Biol
. 2019 Jul;
20(1):142.
PMID: 31315641
We develop CellSIUS (Cell Subtype Identification from Upregulated gene Sets) to fill a methodology gap for rare cell population identification for scRNA-seq data. CellSIUS outperforms existing algorithms for specificity and...
10.
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman A
Nature
. 2019 Jun;
570(7762):462-467.
PMID: 31158845
Individuals vary widely in their responses to medicinal drugs, which can be dangerous and expensive owing to treatment delays and adverse effects. Although increasing evidence implicates the gut microbiome in...